CXCL13 and autoimmune disease: In support of this, serum CXCL13 has been identified as a biomarker of GC activity and production of antibodies after vaccination (44, 45) and of systemic immune activation and disease activity in both infection and autoimmune diseases (14, 15, 18, 43, 46).